Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France

Figures & data

Figure 1. Distribution by age groups of all the tested MenB isolates for the two epidemiological years 2013–2014 and 2018–2019. The numbers of isolates per age group and per year are shown. Due to multiple comparisons, significance level was 0.007.

Figure 2. Distribution of all the tested isolates according to their clonal complexes (CC). The numbers of isolates per CC and per year are shown. UA, unassigned isolates to any of the currently defined CC.

Table 1. Peptide identification number according to PubMLST

fHbp			NHBA
peptides	2013–2014	2018–2019	Peptide	2013–2014	2018–2019
1	27	4	2	25	4
4	11	5	3	22	5
13	6	7	17	5	6
14	25	8	18	6	14
15	10	6	20	15	13
16	6	0	21	14	5
19	17	9	24	10	4
21	7	4	29	18	38
45	5	13	112	3	2
47	10	10	118	9	11
321	0	5	160	6	1
510	14	40	243	0	5
Others	33	24	Others	38	27
Total	171	135	Total	171	135

Figure 3. Distribution (in number of isolates) of fHbp (a) and NHBA (b) peptides of all the tested MenB isolates for the two epidemiological years 2013–2014 and 2018–2019.

Table 2. Coverage rates prediction for the tested isolates according to MATS (with 95% CI) and gMATS (LL-UL)

		2013–2014					2018–2019
		MATS		gMATS			gMATS
Age band	Number	%Coverage	CI95	%Coverage	LL-UL	Number	%Coverage	LL-UL
<1y	35	45.7	37.1–57.1	61.4	45.7–77.1	34	69.1	61.8–76.5
1–4y	26	80.8	65.4–84.6	76.9	65.4–88.5	22	68.2	54.5–81.8
5–9y	6	100.0	100–100	100.0	100–100	6	83.3	66.7–100
10–14y	9	88.9	88.9–100	94.4	88.9–100	6	83.3	83.3–83.3
15–19y	28	67.9	57.1–75	78.6	64.3–92.9	10	100.0	100–100
20–24y	12	91.7	75–100	95.8	50.0–83.3	8	81.3	75.0–87.5
≥25y	52	71.2	59.6–84.6	76.0	51.9–75.0	49	62.2	51.0–73.5
Unknown	3	100.0	100–100	66.7	66.7–66.7	0
Total	171	70.8	60.2–80.1	77.2	66.7–87.7	135	70.7	61.5–80.0

Figure 4. gMATS-based coverage distribution of isolates by clonal complexes represented by more than 5 isolates in each period (two bars per CC; on the left the year 2013–2014 and on the right the year 2018–2019). The isolates of each CC were categorized in covered, unpredictable or non-covered as indicated. The coverage rate with the LL and UL for each CC are indicated above each corresponding bar.

Figure 5. Prediction of 4CMenB coverage by MATS, gMATS and MenDeVAR (for the epidemiological year 2013–2014) and by gMATS and MenDeVAR (for the epidemiological year 2018–2019) of all the tested MenB isolates. The percentages of isolates within each predicted category are shown. For MenDeVAR, covered isolates accounted for both ”exact-match” + ”cross-reactive”. The number of isolates is indicated in the corresponding bars. The estimations of MATS and gMATS coverage are depicted in the Table 2.